Off-label treatment –
what it means, and why it can be reasonable

An approval (or, for devices, CE marking) says: for a specific indication and a specific patient group, sufficient safety and efficacy have been demonstrated. The approval is therefore tightly bound to a concrete indication.

“Off-label” simply means use outside those limits, for example in a different condition, a different age group or a different protocol. Importantly, off-label does not mean “forbidden” or “untested”. The method is approved; only this particular use lies outside the formally reviewed indication.

Off-label use is common across all of medicine, from paediatrics to oncology. You also encounter it in neuromodulation. A concrete example is transcranial pulse stimulation (TPS): in Europe it is CE-marked for Alzheimer’s dementia with the Storz Neurolith. When we use it for a different condition, that is off-label.

How it works mechanistically and where its limits lie is explained in “How does TPS work?”. The point here: the fact that something is off-label says nothing about the quality of the rationale, what matters is how carefully the decision and the consent are handled.

Approvals arise where a large, clearly definable study population can be found and a manufacturer can fund an expensive trial. Many reasonable uses fall through this grid, not because they are implausible, but because the formal trial is (still) missing. Off-label allows existing knowledge to be used responsibly:

• when a plausible mechanism also argues for another condition;
• when early studies or experience suggest benefit, even without formal approval;
• when approved options are exhausted or unsuitable.

In neuromodulation especially, a further idea applies, which we expand below: symptoms arise from individual network dysregulations, and these rarely fit exactly into the box of a single approval.

Off-label demands more care, not less. Before such a treatment begins, we inform you fully: the approval status, what is known and what is not, possible benefits and risks, alternatives and the expected costs. Only once you have understood this and agree do we proceed, this is called informed consent.

Part of our self-image is a clear appraisal of the evidence and transparent progress monitoring. How an off-label application is embedded in an overall concept is shown in Our Program; all of it is discussed in the free initial consultation.

A common misunderstanding is: “If it works, surely there should be one standard protocol for everyone.” With the brain, this is harder. Complaints such as rumination, concentration problems or inner restlessness almost always arise from an individual imbalance across several brain networks, and this pattern differs from person to person, even with the same diagnosis.

That is precisely why, with us, a structured assessment comes before any choice of method, with a qEEG where needed, and we derive the approach from it rather than imposing a one-size-fits-all protocol. Neuromodulation is one building block in that: a gut whose barrier has become leaky keeps sending alarm signals to the brain via the vagus nerve and inflammatory messengers, and a network that is then merely stimulated keeps getting pulled back. That is why lab work, gut, sleep or hormones, depending on the findings, belong to the same plan. This individualisation is medically sound, but it complicates a formal standard approval, which requires large, uniform groups. Here, off-label is often less an exception than an expression of exactly this individualised medicine. Which methods are available is shown in the overview of non-invasive neuromodulation.